Specialized CRO standardizes on ³Ô¹Ï±¬ÁÏ RTSM to drive
operational efficiency and faster study timelines<\/i><\/p>\n
BARCELONA, Spain \u2014 19 March 2025 \u2014 <\/strong> ³Ô¹Ï±¬ÁÏ Systems<\/a> (NYSE: VEEV) today announced that Indero<\/a>, formerly Innovaderm Research, successfully launched its 40th RTSM study on ³Ô¹Ï±¬ÁÏ RTSM<\/a>. By standardizing with ³Ô¹Ï±¬ÁÏ RTSM, Indero has strengthened its clinical trial operations, harnessing advanced RTSM capabilities and expert support to drive efficiency, enhance process consistency, and streamline execution.<\/p>\n \u201cAs we continue to optimize our clinical trial operations, ³Ô¹Ï±¬ÁÏ RTSM has driven more efficient processes and closer collaboration to ensure seamless execution,\u201d said Eric Hardy, senior director, biometrics at Indero. \u201cBecause of this added speed and effectiveness, we can help bring therapies to market faster, allowing our sponsors, sites, and patients to benefit sooner.\u201d<\/p>\n The launch of Indero\u2019s 40th RTSM study highlights the continued collaboration between the two organizations. Since first adopting ³Ô¹Ï±¬ÁÏ RTSM, Indero has worked closely with ³Ô¹Ï±¬ÁÏ to continuously refine and implement standardized processes that drive long-term success for its clinical trials.<\/p>\n \u201cWith its enterprise standard RTSM approach, Indero is achieving greater long-term efficiency and reliability in their studies,\u201d said Steve Simmerman, general manager, ³Ô¹Ï±¬ÁÏ RTSM. \u201cPartnering with Indero to standardize clinical processes will further accelerate study timelines, demonstrating a streamlined approach that can advance the industry.\u201d<\/p>\n Additional Information<\/strong> About Indero<\/strong> <\/p>\n About ³Ô¹Ï±¬ÁÏ Systems<\/strong> ³Ô¹Ï±¬ÁÏ Forward-looking Statements<\/strong> ###<\/center><\/p>\n
\nTo learn more about ³Ô¹Ï±¬ÁÏ\u2019s enterprise standard RTSM, visit www.veeva.com\/rtsm<\/a>.<\/p>\n
\nIndero is a dual-focus CRO for dermatology and rheumatology, with over 25 years of experience in clinical research and trial delivery. Our full-service approach\u2014which includes everything from protocol design and patient recruitment to trial monitoring and biometrics\u2014provides biotech and pharmaceutical sponsors with the rigorous scientific foundation and tailored expertise their studies need to reach the finish line efficiently and effectively. With capabilities in North America, Europe, Latin America, and Asia-Pacific; vast, continuously growing relationships with investigators and patients; and a dedicated research clinic through which we design and execute our own studies, Indero is the ideal partner for clinical needs at a global scale.<\/p>\n
\n³Ô¹Ï±¬ÁÏ is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, ³Ô¹Ï±¬ÁÏ serves more than 1,000 customers, ranging from the world\u2019s largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation<\/a>, ³Ô¹Ï±¬ÁÏ is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com\/eu<\/a>.<\/p>\n
\nThis release contains forward-looking statements regarding ³Ô¹Ï±¬ÁÏ\u2019s products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10- Q for the period ended October 31, 2024, which you can find here<\/a> (a summary of risks which may impact our business can be found on pages 36 and 37), and in our subsequent SEC filings, which you can access at sec.gov<\/a>.<\/p>\n